Details of the Drug

General Information of Drug (ID: DM1EYOF)

Drug Name
BT-200
Indication
Disease Entry ICD 11 Status REF
Von willebrand disease 3B12 Phase 2 [1]
Cross-matching ID
TTD ID
D41PKY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
von Willebrand factor (VWF) TT3SZBT VWF_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Von willebrand disease
ICD Disease Classification 3B12
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
von Willebrand factor (VWF) DTT VWF 2.96E-01 2.47 2.08
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04677803) A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Guardian Theapeutics